Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats

摘要: Background Oxaliplatin has widely been used as a key drug in the treatment of colorectal cancer; however, it causes peripheral neuropathy. Exenatide, glucagon-like peptide-1 (GLP-1) agonist, is an incretin mimetic secreted from ileal L cells, which clinically to treat type 2 diabetes mellitus. GLP-1 receptor agonists have reported exhibit neuroprotective effects on central and nervous systems. In this study, we investigated exenatide oxaliplatin-induced neuropathy rats cultured cells. Methods (4 mg/kg) was administered intravenously twice per week for 4 weeks, mechanical allodynia evaluated using von Frey test rats. Axonal degeneration assessed by toluidine blue staining sciatic nerves. Results Repeated administration oxaliplatin caused day 14 49. Although co-administration extended-release (100 μg/kg) could not inhibit incidence allodynia, facilitated recovery with reparation axonal degeneration. Inhibition neurite outgrowth pheochromocytoma 12 (PC12) cells. Exenatide inhibited degeneration, but did affect cell injury PC12 Additionally, had no effect anti-tumor activity murine colon adenocarcinoma 26 (C-26) cells or C-26 cell-implanted mice. Conclusion These results suggest that may be useful treating induced cancer patients diabetes.